In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tularik: Unique Enough?

Executive Summary

Flush with cash and cachet, Tularik is the highest-valued still-private firm in the biotech industry--worth some $434 million at its last round of financing. To go public, it needs investors to give it a valuation beyond $500 million to launch it into the rarified realm of tradable biotech stocks. Its current investors hope the public will appreciate it for more than its marquee-value CEO, ex-Genentech R&D chief David Goeddel, but an integrated research infrastructure, a strong cash position and its ability to raise more non-equity cash by selling European and American rights to programs already financed by Japanese partners.
Advertisement

Related Content

Amgen Acquires Tularik and Small-Molecule Expertise
Amgen Moves Beyond Proteins
Amgen Moves Beyond Proteins
Tularik & Amgen: A Model of Business Development (and Good News for Biotech, Too)
Tularik & Amgen: A Model of Business Development (and Good News for Biotech, Too)

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel